Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 April 2008, Vol. 111, No. 7, pp. 3867-3871.
Prepublished online as a Blood First Edition Paper on January 30, 2008; DOI 10.1182/blood-2007-08-108654.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-08-108654v1
111/7/3867    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, W.-L.
Right arrow Articles by Chen, S.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, W.-L.
Right arrow Articles by Chen, S.-J.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Brief Report

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Wei-Li Zhao1,2, Yan-Yan Liu1,3, Qun-Ling Zhang1,2, Li Wang1,2, Christophe Leboeuf2,4,5, Yi-Wen Zhang1,2, Jie Ma3, José-Francisco Garcia6, Yong-Ping Song3, Jun-Min Li1, Zhi-Xiang Shen1, Zhu Chen1,2, Anne Janin2,4,5, and Sai-Juan Chen1,2

1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2 Pôle de Recherches Franco-Chinois en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China; 3 Henan Institute of Hematology, Henan Tumor Hospital, Zhengzhou, China; 4 Inserm, U728, Institut d'Hématologie, Hôpital Saint Louis, Paris, France; 5 Université Paris 7-Denis Diderot, Paris, France; and 6 The Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Center (CNIO), Madrid, Spain

The positive regulatory domain I (PRDM1) is a master regulator of terminal B-cell differentiation. However, PRDM1 is not B-cell specific. To determine its role in T-cell lymphoma, PRDM1 expression was investigated in 60 patients. PRDM1{alpha} and PRDM1β transcripts were detected in laser-microdissected T-lymphoma cells in 27 and 14 patients, respectively, mostly in cases with IRF4 expression. PRDM1β was associated with increased c-MYC expression. PRDM1β-positive patients displayed advanced Ann Arbor stage and high-risk International Prognostic Index and were linked to short survival times. In vitro, PRDM1β was related to resistance to chemotherapeutic agents and could be down-regulated by the proteasome inhibitor bortezomib. Kinetic studies showed that bortezomib down-regulation of PRDM1β preceded decreased IRF4 and c-MYC expression. An earlier retaining of cytoplasmic I{kappa}B{alpha} in bortezomib-treated cells was revealed, concomitant with blockade of NF-{kappa}B nuclear translocation. These results demonstrate the involvement of PRDM1β in T-cell lymphoma, with possible therapeutic interference by the proteasome inhibitor.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc., December 1, 2008; 19(12): 2079 - 2083.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020